Speaker Profile
M.D., Director, Natera
Biography
He is a clinician-scientist specializing in nephrology, trained at Hadassah-Hebrew University Hospital in Jerusalem and at Mass General Brigham in Boston. His research focused on discovering novel gene-disease associations in pediatric chronic kidney disease, leveraging whole-exome sequencing analyses and functional validation work conducted at Boston Childrens Hospital. Clinically, he serves as an attending nephrologist at Brigham and Womens Hospital, with experience including expertise in renal genetics through participation in a renal genetics clinic. Through his current role at Natera, he contributes to research and development supporting the Renasight renal genetic testing product and participates in medical affairs activities.
Talk
Turning Kidney Genomics Into Clinical Impact
After decades of gene-kidney disease discovery, monogenic CKD burden was unclear. A 2019 NEJM study showed 10% diagnostic yield in adults with advanced CKD, enabling broad access via Renasight (2020). Subsequent clinic studies report 20% yield, 50% diagnostic reclassification, and 90% actionable changes with significant clinical benefits- now reflected in KDIGONKF guidance.
Clinical Dx Showcase:
Natera
Natera is a global leader in cell-free DNA and genetic testing, with a portfolio spanning prenatal screening, oncology, and organ health. The company develops clinically validated diagnostics to enable earlier detection, more personalized care, and improved patient outcomes.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
